These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
- Redhill Biopharma (RDHL), 790% surge in interest
- Cabaletta Bio (CABA), 670% surge in interest
- Zymeworks (ZYME), 661% surge in interest
- INmune Bio (INMB), 125% surge in interest
- Repligen (RGEN), 113% surge in interest
Pipeline and key clinical candidates for these companies:
RedHill Biopharma is primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers’ diarrhea in adults. RedHill’s key clinical late-stage development programs include: RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria disease; opaganib, or ABC294640, a first-in-class oral SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for hospitalized COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-107, or upamostat, an oral serine protease inhibitor in a Phase 3-stage study as treatment for non-hospitalized symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; and RHB-102 , with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D.
Cabaletta Bio is focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA platform encompasses chimeric antigen receptor T cells for autoimmunity and Cabaletta Bio’s proprietary chimeric autoantibody receptor T cells.
Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, zanidatamab zovodotin, or ZW49, is a novel bispecific HER2 ‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink linker and cytotoxin. Zymeworks is also advancing a preclinical pipeline in oncology and other therapeutic areas.
INmune Bio is focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor, or DN-TNF, product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer, Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression. The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer.
Repligen Corporation develops and commercializes bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The customers served are primarily biopharmaceutical drug developers and contract development and manufacturing organizations, or CDMOs.
Recent news on these stocks:
October 21
SVB Securities analyst Andrew Berens downgraded Zymeworks to Market Perform from Outperform with an $8 price target.
October 19
RedHill Biopharma announced the granting by the United States Patent and Trademark Office, or USPTO, of a further method of use patent that protects the administration of opaganib for the inhibition of a disease caused by a coronavirus in a subgroup population of patients requiring a fraction of inspired oxygen, or FiO2, up to and including 60% at baseline, adding to the existing strong patent suite covering opaganib. The new patent, expiring in 2041, protects the results from a post-hoc analysis from the global Phase 2/3 study in hospitalized patients with COVID-19 pneumonia, the company said.
INmune Bio announced "positive" solid tumor data in multiple cancer lines resistant to NK killing that can be overcome with administration of INKmune. The company’s pre-clinical data show that INKmune primes NK cells from patients and from healthy donors to lyse NK-resistant ovarian, prostate, renal and nasopharyngeal cancer cells. The company identified more than 1,500 proteins that are upregulated in NK cells following INKmune priming and subsequent analysis compared them to NK cells primed with a cytokine cocktail of IL-12, IL-15 and IL-18. Of the 250 most upregulated proteins, 141 are completely unique to INKmune priming and are not upregulated by the cytokines IL-12, IL-15 and IL-18, the company stated.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 15-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RGEN:
